Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen

Phase 1/2 Completed 30 enrolled University of Oxford Medical Research Council · collab Pevion Biotech Ltd · collab Swiss Tropical & Public Health Institute · collab Walter Reed Army Institute of Research (WRAIR) · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.

Timeline

Start: 2005-08
Primary completion: —
Completion: 2006-02

Outcome

Missed primary endpoint

paper no volunteers were completely protected from malaria. PMID 18231580 ↗

Publications

Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One. 2008 Jan 30;3(1):e1493. doi: 10.1371/journal.pone.0001493.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FP9 ME-TRAP	Vaccine	—	—
Subject	MVA ME-TRAP	Vaccine	—	—
Subject	PEV3A	Vaccine	—	—